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Abstract
Cyclin-dependent kinase 5 (CDK-5) appears to play a significant role in peripheral nerve
regeneration as CDK-5 inhibition retards nerve regeneration following nerve crush. Anti-
inflammatory drug acetyl salicylic acid elevates CDK-5 and reduces ischemia – reperfusion injury in
cultured neurons. In this study we have evaluated the effect of acetyl salicylic acid on functional
recovery following sciatic nerve crush in mice. Eighteen Swiss albino mice underwent unilateral
sciatic nerve crush. Test animals received acetyl salicylic acid (100 mg/kg/day, n = 6 or 50 mg/kg/
day, n = 6) and control animals (n = 6) received normal saline for 14 days following surgery.
Functional recovery was assessed with improvement in Sciatic Function Index, nociception and gait.
In comparison with normal saline treatment, acetyl salicylic acid (100 mg/kg/day) significantly
improved functional recovery following sciatic nerve crush. Anti-inflammatory drug acetyl salicylic
acid appears to be a promising agent for treating peripheral nerve injuries and hence elucidation of
its neuroprotective pathways is necessary.
Background
The injured adult mammalian peripheral nerves, in con-
trast with axons injured inside central nerve tracts, show
vigorous regeneration [1]. The exact physiological and
molecular signals involved in inducing the regenerative
process are largely unknown. In addition to the induction
of transcription factors, adhesion molecules, growth asso-
ciated proteins and structural components required for
axonal elongation, intracellular signalling molecules that
control cell cycle and differentiation appears to play a
major role in nerve regeneration process [1].
Cyclins and the cyclin dependent kinases (CDKs) play a
central role in regulating the cell cycle progression in all
eukaryotic organisms [2]. Cyclin-dependent kinase – 5
(CDK-5) is a member of these cyclin-dependent kinase
family of serine/threonine kinases. CDK-5 along with its
activators, p35 and p39, is predominantly expressed in
post-mitotic neurons [3]. CDK-5 appears to be involved in
active reorganization of the actin cytoskeleton during neu-
rite outgrowth [4]. Enhanced CDK-5 activity and expres-
sion of p35 are associated with differentiation of cultured
neuronal cells as well as accelerated neurite outgrowth [4].
Namgung et al [5] reported a high expression of CDK-5
and p35 in regenerating nerves. In their experiments inhi-
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vitine and olomoucine, led to reduction in CDK-5 activity
and retardation of nerve regeneration [5].
Non-steroidal anti-inflammatory agent acetyl salicylic
acid (ASA), in addition to its well known inhibitory action
on cyclooxygenases, affects several cellular signalling
pathways involved in regulation of cellular proliferation
and differentiation [6]. One of the newly identified
actions of ASA is being the induction of p 35 synthesis and
activation of CDK-5 [6]. ASA has shown a neuroprotective
effect in an in-vitro model of neuronal ischemia reper-
fusion injury [6]. However its effect on peripheral nerve
injuries is unknown.
In this study we have evaluated the effect of ASA at two
doses (100 mg/kg/day and 50 mg/kg/day) on functional
recovery following peripheral nerve injury using mouse
sciatic nerve crush model.
The following drugs were used for this study: Urethane
(Sigma, USA), Normal Saline (Baxter, India) and ASA
(Alta Labs, India).
Swiss albino mice (25 – 30 gms) of both sexes were ran-
domly allocated into three different treatment and control
groups. Animals received food and water ad libitum and
were kept on a 12-hour light/dark cycle. Animals were
kept under the accordance of protocols approved by the
institutional animal care and use committee.
Mice were subjected to sciatic nerve crush as described ear-
lier [7]. In brief adult mice were anesthetized with 150
mg/100 g intraperitoneal urethane. The area above the
right lower thigh was shaved and sterilized with betadine
and 70% surgical spirit. A 1 cm incision was made in the
skin above the lower thigh between the gluteus maximus
muscle and the biceps femoris muscle. The muscles were
teased apart with scissors and the sciatic nerve exposed.
Sciatic nerve was placed in a 1 mm wide needle holder
and crushed for 20 sec. The holder was rotated 90° and
the crush was repeated at the same site. The nerve was
replaced under the muscle and the incision was sutured.
Completeness of the crush was established by examining
the loss of sensory and motor function in the operated
limb. Digits in the operated limb were pinched using a
blunt forceps. Absence of foot withdrawal and vocaliza-
tion was noted as loss of sensory and motor function. For
sham controls the sciatic nerve of the right hind limb was
surgically exposed but no crush was made.
The animals in three groups (n = 6 each) received normal
saline (0.9 % NaCl, 0.5 ml, ip), ASA (50 mg/kg/day, ip)
and ASA (100 mg/kg/day, ip) respectively for 14 days fol-
lowing surgery.
Evaluation of sciatic function index (SFI) [8] and gait [7]
was done on day 0 i.e. before surgery and on days 1 and15
following surgery. Mice were held by the chest and their
hind feet were pressed down onto a stamp pad soaked
with water soluble black ink. Mice were immediately
allowed to walk along a confined walkway 6 cm wide by
30 cm long with a dark shelter at the end of the corridor
leaving its foot prints on the paper that is cut to the appro-
priate dimensions and placed on the floor of the corridor.
The tracks were evaluated for three different parameters:
(1) distance from the heel to the third toe, the print length
(PL); (2) distance from the first to the fifth toe, the toe
spread (TS); and (3) distance from the second to the
fourth toe, the intermediary toe spread (ITS). All three
measurements were taken from the experimental (E,
undergoing sciatic nerve crush) and normal (N) limbs.
Using the following formula derived by Bain et al [9] SFI
was calculated as,
SFI = -38.3 [(EPL - NPL)/NPL] + 109.5 [(ETS - NTS)/
NTS] + 13.3 [(EIT - NIT)/NIT] - 8.8
The SFI was analysed as: An SFI equal to 100 indicates sig-
nificant impairment, whereas an SFI oscillating around 0
is considered to reflect normal function.
Animals were allowed to walk on a platform as well as on
an inclined plane for 2 min each. Subjective scores were
assigned on the basis of hind limb movement and its pos-
ture while ambulating. Mice moving both the hind limbs
uniformly given 3, if the operated limb was moving with
deformity it received 2, scored as 1 if the operated limb
was moving seldom and 0 – when no movement was seen
in the operated hind limb.
Nociceptive function was evaluated by observing the
withdrawal reflex of the hind limb and vocalization in
response to noxious stimulation like mechanical stimula-
tion (pinch test) and pricking the plantar aspect of the lat-
eral part of the foot with a needle [7]. Animals were
evaluated daily, till the recovery of nociceptive function.
The entire regimen was repeated twice and then all the val-
ues from multiple experiments were averaged. Statistical
evaluation was conducted using multiple comparisons
and Mann Whitney U test. Data are depicted as mean ± sd.
'P' values < 0.05 were considered significant.
In all animals SFI score prior to surgery was 0, gait score
was three and nociceptive function was intact. Following
sciatic nerve crush in all animals, except sham controls,
SFI scores became 100 and gait scores were reduced to 0
and there was loss of nociceptive function. In sham con-
trols there was no change in SFI scores and gait scores,
while nociceptive function remained intact.Page 2 of 4
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tion in normal saline treated mice as shown by reduction
in SFI scores, improvement in gait scores and recovery of
nociceptive function (table 1). There was no significant
difference, in the functional parameters, between animals
treated with 50 mg/kg/day of ASA and animals receiving
normal saline treatment. However animals treated with
100 mg/kg/day of ASA showed statistically significant
reduction in SFI scores and improvement in gait and
exhibited an early recovery in nociceptive function (table
1).
ASA is one of the most widely used analgesic, anti-pyretic
and anti-inflammatory drug. ASA exerts these effects
through inhibition of cyclooxygenases (COX) [6]. How-
ever novel COX-independent actions of ASA like, inhibi-
tion of excitatory amino acid release, NF-kappa beta
(Nfkb) translocation to the nucleus and expression of
inducible nitric acid synthase (iNOS) following cerebral
ischemia are projecting ASA as a promising neuroprotec-
tive agent for treating stroke [10].
Our results show that ASA, at anti-inflammatory dose, sig-
nificantly accelerates functional recovery following
peripheral nerve crush. Even though ASA at 50 mg/kg/day
dose showed marginally higher functional recovery it was
not significant in comparison with normal saline treat-
ment. Hence the neuroprotective action of ASA following
peripheral nerve injuries appears to be dose-dependent
with maximum benefit seen with 100 mg/kg/day.
Even though our preliminary study shows the neuropro-
tective action of ASA in peripheral nerve injuries, data
regarding the molecular mechanisms leading to the neu-
roprotective action is still lacking. We have not given the
histological and molecular evidence for neuroprotective
action of ASA. This may be considered as a limitation to
our study. Based on the previous reports describing the
role of CDK-5 in nerve regeneration [5] and effect of ASA
on CDK-5 [6] it may be assumed that ASA promotes nerve
regeneration following peripheral nerve injury through
activation of CDK-5. However ASA also affects prostaglan-
din synthesis, iNOS expression, Nfkb translocation,
mitogen activated protein (MAP) kinase pathway etc
which can modulate nerve regeneration following periph-
eral nerve injury. Hence understanding the molecular
pathways leading to the neuroprotective action of ASA is
necessary.
In conclusion our preliminary study shows that acetyl sal-
icylic acid accelerates functional recovery following
peripheral nerve injury and it appears to be a promising
agent for treating peripheral nerve injuries. Further studies
aimed at understanding the molecular mechanisms
involved in the neuroprotective action of acetyl salicylic
acid are required.
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Table 1: Improvement in sensorimotor function following sciatic nerve crush
Treatment groups 
(n = 6 animals in each group)
Improvement in SFI scores 
(in %, as on day 15)
Improvement in gait scores 
(in %, as on day 15)
Time taken for sensory recovery 
(number of days)
Normal saline 38.2 ± 1.8 25.12 +/- 4.8 17.80 +/- 3.7
Acetyl salicylic acid (50 mg/kg/day) 41.7 ± 2.4 31.3 ± 1.7 16.1 ± 3.1
Acetyl salicylic acid (100 mg/kg/day) 55.3 ± 1.7* 48.35 +/-1.7* 14.05 +/- 2.0*
Data are depicted as mean ± SD. 'P' values: < 0.05; * vs control (Mann-Whitney U test with multiple comparisons)Page 3 of 4
(page number not for citation purposes)
Journal of Brachial Plexus and Peripheral Nerve Injury 2007, 2:3 http://www.JBPPNI.com/content/2/1/3Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
4. MGT – Concept, Data analysis, Manuscript preparation
References
1. Makwana M, Raivich G: Molecular mechanisms in successful
peripheral regeneration.  FEBS Journal 2005, 272:2628-38.
2. Shiff SJ, Qiao L, Tsai L-L, Rigas B: Sulindac Sulfide, an Aspirin-like
Compound, Inhibits Proliferation, Causes Cell Cycle Quies-
cence, and Induces Apoptosis in HT-29 Colon Adenocarci-
noma Cells.  J Clin Invest 1995, 96:491-503.
3. Harada T, Morooka T, Ogawa S, Nishida E: ERK induces p35, a
neuron-specific activator of Cdk5, through induction of Egr1.
Nat Cell Biol 2001, 3:453-59.
4. Smith D: Cdk5 in neuroskeletal dynamics.  Neurosignals 2003,
12:239-51.
5. Namgung UK, Choi B-H, Park S, Lee J-L, Seo S-H, Suh B-C, Kim K-T:
Activation of cyclin-dependent kinase 5 is involved in axonal
regeneration.  Mol Cell Neurosci 2004, 25:422-32.
6. Vartiainen N, Keksa-Goldsteine V, Goldsteins G, Koistinaho J: Aspi-
rin provides cyclin-dependent kinase 5-dependent protec-
tion against subsequent hypoxia/reoxygenation damage in
culture.  J Neurochem 2002, 82:329-35.
7. Subbanna PK, Tyagi MG: PAF antagonism modifies neuropro-
tective action of histone deacetylase and calcineurin phos-
phatase inhibitors in mice.  Indian J Exp Biol 2006, 44:886-91.
8. Varejao ASP, Melopinto P, Meek MF, Fillipe VM, Jose BC: Methods
for the experimental functional assessment of rat sciatic
nerve regeneration.  Neurological Res 2004, 26:186-94.
9. Bain JR, Mackinnon SE, Hunter DA: Functional evaluation of com-
plete sciatic, peroneal and posterior tibial nerve lesions in
the rat.  Plast Reconstr Surg 1989, 83:129-38.
10. Moro MA, De Alba J, Cardenas A, De Cristobal J, Leza JC, Lizasoain
I, Diaz-Guerra MJ, Bosca L, Lorenzo P: Mechanisms of the neuro-
protective effect of aspirin after oxygen and glucose depriva-
tion in rat forebrain slices.  Neuropharmacology 2000, 39:1309-18.Page 4 of 4
(page number not for citation purposes)
